13 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
. Given the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel
DRS/A
hwagtwr4sa4g
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
x9725fonq8x gxnp8
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
ndwne2fn5 il5z3
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
st1s8ej5 j3
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
pev c0lt2543e
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
bxedyo77 4e
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
xvdf9 o9f
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
9styjrrq953
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next